AstraZeneca's Phase III Trial of Baxdrostat in Primary Aldosteronism Underway
AstraZeneca is conducting Phase III trial to evaluate the efficacy and safety of baxdrostat in patients with Primary Aldosteronism.
Asset / Drug
Drug and asset intelligence for baxdrostat with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.